Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.95 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | CES1 | P23141 | 2/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terephthalic Acid SCHEMBL28023943 | 0.98 | TDP1 (1.00) | TDP1SRD5A2MEN1KMT2ACES1 | |
| 4-Nitrobenzoic Acid SCHEMBL43476 | 0.98 | TDP1 (1.00) | TDP1SRD5A2MEN1KMT2ACES1 | |
| 4-Nitrobenzoic Acid SCHEMBL1566327 | 0.95 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2ACES1 | |
| 4-Nitrobenzoic Acid SCHEMBL11773857 | 0.95 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2ACES1 | |
| 4-Nitrobenzoic Acid SCHEMBL17332086 | 0.95 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2ACES1 | |
| 4-Nitrobenzoic Acid SCHEMBL10720762 | 0.95 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2ACES1 | |
| 4-Nitrobenzoic Acid SCHEMBL8025368 | 0.95 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2ACES1 | |
| 4-Nitrobenzoic Acid SCHEMBL321099 | 0.95 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2ACES1 | |
| 4-Nitrobenzoic Acid SCHEMBL9316553 | 0.95 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2ACES1 | |
| 4-Nitrobenzoic Acid SCHEMBL10439552 | 0.95 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2ACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192875-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10584109-B2 | Processes for preparing antiviral compounds | Gillead Pharmasset LLC (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2018-06-28 | — | — | US | disclosed |
| US-9890134-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670187-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3154984-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015191437-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584109-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | TDP1 1033/4885SRD5A2 1567/4885MEN1 3235/4885 |
| US-11192875-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | TDP1 1033/4885SRD5A2 1567/4885MEN1 3235/4885 |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | TDP1 1033/4885SRD5A2 1567/4885MEN1 3235/4885 |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | TDP1 1033/4885SRD5A2 1567/4885MEN1 3235/4885 |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | TDP1 1033/4885SRD5A2 1567/4885MEN1 3235/4885 |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | TDP1 1033/4885SRD5A2 1567/4885MEN1 3235/4885 |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | TDP1 1033/4885SRD5A2 1567/4885MEN1 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.